Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA5 | P22460 | 12/20 | 0.57 |
| ▸ | KCNH2 | Q12809 | 7/20 | 0.54 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | CFTR | P13569 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | GOPC | Q9HD26 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9945340 | 1.00 | KCNA5 (0.57) | KCNA5KCNH2CYP19A1SMN1; SMN2CFTR | |
| SCHEMBL1242950 | 1.00 | KCNA5 (0.57) | KCNA5KCNH2CYP19A1SMN1; SMN2CFTR | |
| SCHEMBL1240484 | 0.96 | KCNA5 (0.54) | KCNA5KCNH2CYP19A1SMN1; SMN2 | |
| SCHEMBL1242139 | 0.95 | KCNA5 (0.60) | KCNA5KCNH2CYP19A1SMN1; SMN2 | |
| SCHEMBL1242788 | 0.88 | KCNA5 (0.44) | KCNA5KCNH2CYP19A1SMN1; SMN2CFTR | |
| SCHEMBL9945327 | 0.88 | KCNA5 (0.44) | KCNA5KCNH2CYP19A1SMN1; SMN2CFTR | |
| SCHEMBL9945357 | 0.88 | KCNA5 (0.44) | KCNA5KCNH2CYP19A1SMN1; SMN2CFTR | |
| SCHEMBL1243025 | 0.84 | KCNA5 (0.45) | KCNA5KCNH2CYP19A1 | |
| SCHEMBL12890149 | 0.83 | KCNA5 (0.42) | KCNA5KCNH2CYP19A1 | |
| SCHEMBL1242920 | 0.83 | KCNA5 (0.43) | KCNA5KCNH2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-8669274-B2 | Metalloenzyme inhibitor compounds | VIAMET PHARMACEUTICALS, INC. (US) | 2014-03-11 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | VIAMET PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149729-A1 | METALLOENZYME INHIBITOR COMPOUNDS | MMEL1, GPX1, MPO | KCNA5 2402/4885KCNH2 2250/4885CYP19A1 898/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.